文献速递消化与肝胆胰病理细胞病理与分子病理

骨与软组织肿瘤免疫组化更新:经济替代分子检测

Update on immunohistochemistry in bone and soft tissue tumors: Cost-effectively replacing molecular testing with immunohistochemistry.
PubMed 文献 · Hum Pathol · 2023-12-20

本文综述骨与软组织肿瘤中作为分子改变替代标志物的免疫组化抗体,强调其可替代资源密集的细胞遗传和分子遗传分析,具有快速、经济、可重复的优势,结合分子发病机制知识可在多数病例中实现准确诊断。

要点

  • 免疫组化可作为复发性基因融合、扩增和点突变的替代标志物。
  • 免疫组化优势包括周转快、成本效益高和判读可重复。
  • 合理应用免疫组化标志物结合分子发病机制知识可准确诊断多数病例。

核心结论

  • 免疫组化可作为骨与软组织肿瘤中复发性基因融合、扩增和点突变的替代标志物,在特定情境下替代细胞遗传和分子遗传分析。

研究设计与样本

  • 本文为综述,概述骨与软组织肿瘤中作为分子改变替代标志物的免疫组化标志物,强调分子相关性和判读挑战。

主要发现

  • 多种抗体可作为复发性基因融合、扩增和点突变的替代标志物。
  • 免疫组化具有快速周转、成本效益和判读可重复性等优势。

临床怎么用

  • 合理应用免疫组化标志物并结合分子发病机制知识,可在多数病例中实现准确诊断。

局限性

  • 强调判读挑战和陷阱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Soft tissue tumors form part of a challenging domain in diagnostic pathology owing to their comparative rarity, astonishing histologic diversity, and overlap between entities. Many of these tumors are now known to be defined by highly recurrent, or, in some instances, unique molecular alterations. Insights from gene profiling continue to elucidate the wider molecular landscape of soft tissue tumors; many of these advances have been co-opted by immunohistochemistry (IHC) for diagnostic applications. There now exists a multitude of antibodies serving as surrogate markers of recurrent gene fusions, amplifications, and point mutations, which, in certain settings, can replace the need for more resource and time-intensive cytogenetic and molecular genetic analyses. IHC presents many advantages including rapid turnaround time, cost-effectiveness, and interpretative reproducibility. A sensible application of these immunohistochemical markers complemented by a working knowledge of the molecular pathogenesis of bone and soft tissue tumors permits accurate diagnosis in the majority of cases. In this review, we will outline some of these biomarkers while emphasizing molecular correlates and highlighting interpretative challenges and pitfalls.

来源:Hum Pathol,查看原文。版权归原作者所有。

引用

  1. Wakefield C, Hornick JL. Update on immunohistochemistry in bone and soft tissue tumors: Cost-effectively replacing molecular testing with immunohistochemistry. Hum Pathol. 2023. PMID: 38135060. doi:10.1016/j.humpath.2023.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。